Alberto Aimo

In LVH, photon-counting #YesCCT provided #whyCMR level data on LV geometry, function, scar, & ECV. Late iodine enhancement closely matched CMR-LGE & CT-ECV tracked CMR-ECV, while also providing coronary CTA. jacc.org/doi/10.1016/j.… #JACCIMG @mauripieroni72 @MicheleEmdin

Natural History of Asymptomatic Phenotypically Mild HCM: Insights From the SHaRe Registry Approximately 21% of patients with phenotypically mild HCM developed MACE over medium-term follow-up. @JACCJournals jacc.org/doi/10.1016/j.…

Myocardial Scar Assessment Using Artificial Intelligence-Powered Contrast-Free MRI: Prospective Multicenter Virtual Native Enfantement Accurate myocardial scar quantification can be achieved without contrast agents in high-quality and clear VNE images. jacc.org/doi/10.1016/j.…

Trientine for hypertrophic cardiomyopathy: a phase 2 trial. Read more in EHJ. doi.org/10.1093/eurhea… #HypertrophicCardiomyopathy #Trientine #CardiologyResearch #Phase2Trial #EHJ @ESCardio @ESCJournals

📢 #AF ablation in cardiac #amyloidosis: results from the multicentre AMYL-AF study 👉 ow.ly/zc6850ZnEG1 @EuropaceEiC @GiulioConteMD @Dominik_Linz @FraSantoroMD @AndyZhangMD @marcovitoloMD @DavideMei93 #Europace #arrhyhtmias #AF #amyloidosis

What’s new in #HF Feb 2026? 🔗 doi.org/10.1093/ejhf/x… 🫀 HF classification & biology 💊 #Polypharmacy #obesity advanced CKD ❤️ HR physiology in #HFpEF 🧠 #SGLT2i & neurocognition 🤰 #PPCM & CS 🧬 #HCM evolving diagnosis & therapy @DaniTomasoni @AlbertoAimo90 @ESC_Journals #EJHF

Academic publishing is long overdue for real disruption. As I’ve been posting about recently, the current system is fundamentally broken: paywalls that block access to research, sky-high article processing charges that favor well-funded labs, months-long review cycles that slow down medical progress, and peer reviewers who do the heavy lifting for free with zero recognition or career benefit. We are introducing OpenSource: Cardiology, a physician-led option built by and for the cardiovascular community. 🔓 100% open access - free for every reader, worldwide 💵 Zero publication fees for original research (sustainably funded, not on authors) ©️ Authors retain full ownership of their work 🤖 Smart AI to accelerate submissions, reviewer matching, formatting, and integrity checks - without replacing human scientific judgment 🧠 Reimagined peer review with actual incentives: gift cards, opportunities to publish editorials and earn co-authorship, and paths to advancement in the editorial team We are open for business! Follow us @opensourcecards, submit your manuscripts, and signup as a reviewer at opensourcecardiology.org. Join us and be part of the solution! Thanks to everyone who has advised @jtsaxon and I on this journey including @djc795 @CMichaelGibson @DrDamluji @AndrewJSauer @heartofthemater @ShahzebKhanMD @MichaelNassifMD @venkmurthy @AmitGoyalMD @JavedButler1 and others!

We have developed #FINDHF , a scalable prediction model using electronic health records to identify undiagnosed #heartfailure risk. Validated in the UK, Japan, USA & Taiwan (millions of patients), it shows strong performance & high NPV. share.google/5h3S03aWPfiHF4…

🗞️ Risk models for sudden cardiac death in cardiomyopathies: clinical, methodological and ethical challenges @ESC_Journals @GiuseppeGalati_ @AmrAbdin10 @HanCardiomd bit.ly/4f06nA7

Topline results from the CARDIO-TTRansform trial Primary was not met Subgroup (monotherapy) reported nominally significant (HR 0.71) ~57% baseline tafamidis use Trial will be presented at ESC ir.ionis.com/news-releases/…

Effects of #Acoramidis on Kidney Function in Transthyretin Amyloid Cardiomyopathy | Circulation: Heart Failure ahajournals.org/doi/10.1161/CI…

A must-read in @CircImaging by @SNagueh! 🫀 Past, Present & Future of Diastolic Function – Key Takeaways 🔹 Diastolic assessment has evolved from invasive hemodynamics to a comprehensive #EchoFirst approach. 🔹 The 2025 ASE algorithm simplifies evaluation, reduces indeterminate cases (~0.2%), & improves accuracy for estimating LV filling pressures. 🔹 Age-adjusted e', E/e', PASP, LA strain, pulmonary vein flow, & IVRT are central to modern assessment. 🔹 The algorithm has been validated in 951 patients & adds diagnostic value for HFpEF beyond clinical scores. 🔹 Emerging tools—including LA chamber stiffness, shear-wave imaging, valve opening timing, & AI—may further transform diastology. 👉bit.ly/3Rr3dfP #CardioX #Cardiotwitter

Beyond the Valve: Redefining Moderate Aortic Stenosis Management - Is a pre-emptive strategy better? do we need to wait until severe? read our editorial @EFerrerSistach 👉 onlinejase.com/article/S0894-… @victoria_vilata @iCorGTrias @GTRecerca @ASE360

🚨 Major update in the ATTR amyloidosis world: the CARDIO-TTRansofrm trial missed its primary endpoint. What does this mean for our patients & the field? My early thoughts below... astrazeneca.com/media-centre/p…

Treatment of systemic amyloidosis is evolving rapidly. This comprehensive review highlights recent advances in AL and ATTR amyloidosis. @BU_Amyloidosis Systemic light chain and transthyretin amyloidosis—treatment advanceme... sciencedirect.com/science/articl…

Low-risk heart failure may not be low risk. Even with low NT-proBNP, a 23-protein score separated mortality nearly 5-fold. Proteomics unmasks hidden risk. Read more in #EHJ. doi.org/10.1093/eurhea… #HF #cardiotwitter @ESC_Journals @escardio

Prevention is the heart

Join us on Monday, July 20, 2026, from 9:30-10:30 am ET for Baim Grand Rounds with @scottdsolomon, presenting “Heart Failure with Mildly Reduced or Preserved Ejection Fraction – the Long and Winding Road.” Zoom link: us06web.zoom.us/j/85331817426

Transforming clinical decisions with artificial intelligence: the HYPERMARKER project academic.oup.com/eurheartj/arti… #AI #ClinicalDecisions #EHJ

Where do you land on AI in publishing?! Accelerating knowledge, integrating data, improving efficiency/consistency VS fabricated content, biased outputs, erosion of accountability Need transparency, provenance, enforceable human responsibility: academic.oup.com/eurheartj/arti…